证券简称：通策医疗 证券代码：600763 编号：临 2025-023 通策医疗股份有限公司 关于修订《公司章程》及其他制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 通策医疗股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开第 十届董事会第十次会议及第十届监事会第九次会议，审议通过了《关于公司 修订<公司章程>及其他制度的议案》。现将有关情况公告如下： 一、《公司章程》修订情况 为进一步提升公司的规范运作水平，根据《中华人民共和国公司法》《关于 新<公司法>配套制度规则实施相关过渡期安排》《上市公司章程指引》《上海证 券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规 范运作》等有关规定，对《公司章程》进行修订。具体修订情况如下。 | 原《公司章程》 | 修改后的《公司章程》 | | --- | --- | | 第一条 为维护公司、股东和债权 | 第一条 为维护公司、股东、职工 | | 人的合法权益，规范公司的组织和行 | 和债权人的合法权益，规范公司的组 | | ...

TC-DSH-001 公司章程 通策医疗股份有限公司 章程 二○二五年五月 第 1页，共 46页 TC-DSH-001 公司章程 目录 第 2页，共 46页 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东的一般规定 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 第五章 董事会 第一节 董事 第二节 董事会 第三节 独立董事 第四节 董事会专门委员会 第六章 高级管理人员 第七章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第八章 通知和公告 第一节 第一节通知 第二节 公告 第 3页，共 46页 TC-DSH-001 公司章程 通策医疗股份有限公司章程 第一章 总则 TC-DSH-001 公司章程 第九章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十章 修改章程 第十一章 附则 经北京市证券监督管理委员 ...

证券代码：600763 证券简称：通策医疗 编号：临 2025-024 一、关联交易概述 1. 关联交易的主要内容 1/6 通策医疗股份有限公司（以下简称"通策医疗"或"公司"）全资子公 司浙江通策口腔医院投资管理集团有限公司（以下简称"通策口腔投资"） 收购上海存济口腔门诊部有限公司（以下简称"标的公司"）99%股权， 全资子公司杭州通盛医疗投资管理有限公司收购标的公司 1%股权，交易 总金额为 4600 万元。 标的公司为上海通策口腔医院有限公司全资子公司，上海通策口腔医院 有限公司法人代表为吕建明先生，为公司实际控制人，本次交易构成关 联交易。 本次交易未导致公司主营业务、资产、收入发生重大变化，不构成《上 市公司重大资产重组管理办法》规定的重大资产重组、不存在重大法律 障碍。 截至本次关联交易前，过去 12 个月内，公司及子公司分别与目标企业 未发生关联交易。根据《公司章程》及相关规定，本事项无须提交股东 大会审议。 通策医疗全资子公司通策口腔投资收购上海存济口腔门诊部有限公司 99% 股权，全资子公司杭州通盛医疗投资管理有限公司收购标的公司 1%股权，交易 总金额为 4600 万元，交易资金来源为自 ...

证券简称：通策医疗 证券代码：600763 编号：临 2025-022 通策医疗股份有限公司关于取消监事会的公告 通策医疗股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开第十届监 事会第九次会议，审议通过了《关于取消监事会及免去监事职务的议案》，现将有关 事项公告如下： 根据 2024 年 7 月 1 日起实施的《中华人民共和国公司法》、《上市公司章程指 引》（2025 年修订）等相关法律法规的规定及中国证券监督管理委员会于 2024 年 12 月 27 日发布的《关于新配套制度规则实施相关过渡期安排》，结合公司的实际情况 及需求，公司不再设置监事会，免去监事张晓露先生、赵敏女士，原监事会的职权由 董事会审计委员会行使，同时废止《公司监事会议事规则》，并对《公司章程》中相 关条款做出相应修订。本次取消监事会事项不会对公司治理、生产经营产生不利影响。 本议案尚需提交公司股东大会审议。在股东大会审议通过之前，监事会及监事仍 应当按照有关法律、行政法规和《公司章程》的规定继续履行职责，确保公司的正常 运作，维护公司和全体股东利益。 公司监事会的全体监事在职期间勤勉尽责，为公司规范运作和健康发展 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [34]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a gain of 3.86% from August 8 to August 21, 2025, lagging behind the index by approximately 0.35 percentage points [13]. - All sub-sectors within the industry recorded positive returns during the same period, with the medical consumables and medical devices sectors leading with increases of 6.80% and 5.88%, respectively [14]. - Approximately 73% of stocks in the industry achieved positive returns, indicating a broad recovery across the sector [15]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was about 54.73 times as of August 21, 2025, with a relative PE to the CSI 300 of 4.23 times, showing little change in valuation [19][28]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, gaining 3.86% from August 8 to August 21, 2025, which is 0.35 percentage points lower than the index [13]. - All sub-sectors recorded positive returns, with medical consumables and medical devices leading at 6.80% and 5.88% increases, respectively [14]. - About 73% of stocks in the industry had positive returns during this period [15]. - The industry valuation remained stable, with a PE ratio of 54.73 times and a relative PE of 4.23 times compared to the CSI 300 [19]. 2. Industry News - Significant developments include the initiation of large-scale collective procurement for high-value medical consumables, with notifications issued by Sichuan and Inner Mongolia regarding historical procurement data for cardiac occluders [26]. - The report highlights the importance of the collective procurement initiative led by Fujian province, which may have national implications for medical consumables [26]. 3. Company Announcements - Notable announcements include the approval of a new clinical trial for a drug by Teva Biopharmaceuticals, indicating ongoing innovation and development within the sector [27]. 4. Industry Outlook - The report suggests maintaining an "Overweight" rating, emphasizing the potential for recovery in previously underperforming sectors such as medical consumables and devices, especially as the industry enters a period of intensive earnings disclosures [28]. - Recommended stocks for attention include leading companies across various segments, such as Mindray Medical (300760) and Aier Eye Hospital (300015), which are expected to benefit from favorable market conditions [30].

8月21日，沪深两融数据显示，通策医疗获融资买入额0.77亿元，居两市第366位，当日融资偿还额0.79 亿元，净卖出276.83万元。 来源：金融界 融券方面，当日融券卖出0.62万股，净卖出0.60万股。 最近三个交易日，19日-21日，通策医疗分别获融资买入0.68亿元、0.73亿元、0.77亿元。 ...

证券之星消息，截至2025年8月20日收盘，通策医疗(600763)报收于46.41元，上涨1.31%，换手率 2.34%，成交量10.49万手，成交额4.84亿元。 8月20日的资金流向数据方面，主力资金净流入2909.43万元，占总成交额6.01%，游资资金净流出 726.79万元，占总成交额1.5%，散户资金净流出2182.63万元，占总成交额4.51%。 近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-20 | 46.41 1.31% | 2909.43万 | 6.01% | -726.79万 | -1.50% | -2182.63万 | -4.51% | | 2025-08-19 | 45.81 -0.80% | -5323.34万 | -10.04% | 2071.69万 | 3.91% | 3251.65万 | 6.13% | | 2025-08-18 | 46.18 2.26% ...

Company Overview - Tongce Medical's closing price on August 20 was 46.41 yuan, with an increase of 1.31%, resulting in a rolling PE ratio of 40.53, the lowest in 16 days, and a total market value of 20.759 billion yuan [1] - The company's main business includes providing oral medical services and research, with key products being medical services, product sales, construction engineering, and comprehensive service fees [1] Financial Performance - For the first quarter of 2025, Tongce Medical reported operating revenue of 745 million yuan, a year-on-year increase of 5.11%, and a net profit of 184 million yuan, up 6.22%, with a gross profit margin of 44.21% [1] Industry Comparison - The average PE ratio for the medical services industry is 49.21, with a median of 65.65, placing Tongce Medical at the 25th position within the industry [1] - The company has a total market value of 20.759 billion yuan, compared to the industry average market value of 20.077 billion yuan and the median of 71.97 billion yuan [2]

Market Overview - On August 20, the medical services sector rose by 0.33% compared to the previous trading day, with Haocen Medical leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Top Gainers in Medical Services - Haocen Medical (002622) closed at 3.96, up 10.00% with a trading volume of 827,000 shares and a transaction value of 322 million yuan [1] - Meinian Health (002044) closed at 5.87, up 4.45% with a trading volume of 2,284,200 shares and a transaction value of 1.323 billion yuan [1] - Baicheng Pharmaceutical (301096) closed at 56.47, up 3.31% with a trading volume of 72,900 shares and a transaction value of 401 million yuan [1] Top Losers in Medical Services - Innovation Medical (002173) closed at 23.05, down 7.21% with a trading volume of 1,255,900 shares and a transaction value of 2.968 billion yuan [2] - Boji Pharmaceutical (300404) closed at 12.36, down 6.01% with a trading volume of 819,000 shares and a transaction value of 1.015 billion yuan [2] - Nanmo Biological (688265) closed at 61.50, down 5.38% with a trading volume of 32,800 shares and a transaction value of 201 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 2.075 billion yuan from institutional investors, while retail investors saw a net inflow of 1.893 billion yuan [2][3] - The top net inflow from retail investors was in Meinian Health (002044) with 201 million yuan, despite a net outflow from institutional investors [3] - Haocen Medical (002622) had a net inflow of 114 million yuan from institutional investors, but also faced significant outflows from retail investors [3]

融券方面，当日融券卖出0.56万股，净卖出0.31万股。 来源：金融界 最近三个交易日，14日-18日，通策医疗分别获融资买入0.73亿元、0.68亿元、1.01亿元。 8月18日，沪深两融数据显示，通策医疗获融资买入额1.01亿元，居两市第352位，当日融资偿还额1.05 亿元，净卖出349.45万元。 ...